Tissue Polypeptide-Specif ic Antigen and CA 125 as Serum Tumor Markers in Ovarian Carcinoma

Abstract

The serum levels of tissue polypeptide-specific (TPS) antigen were measured using the M3 monoclonal antibody in an enzyme immunoassay in 33 patients with ovarian cancer, in 26 women with benign pelvic masses and in 26 women with a laparoscopically proven normal pelvis. The results were compared with the serum levels of the CA 125 antigen. At a cutoff level of 135 U/l for TPS and 20 U/l for CA 125 (95th percentile of the healthy controls), the sensitivity of the tests for detecting a malignant tumor was 77% for TPS and 87% for CA 125. The specificities were 85% for TPS and 92% for CA 125. Adding TPS to CA 125 did not increase the diagnostic values compared to using the CA 125 test alone. For both markers, the rate of positivity was higher in advanced stage than in early-stage ovarian cancer. No correlation between marker levels and survival was found. Serial determinations performed with 4 patients during therapy and follow-up showed that both TPS and CA 125 are good predictors of tumor response and recurrence.

Clinical Evaluation of Serum Tissue Polypeptide Specific Antigen in Patients with Thyroid Carcinoma

“…Serum Tg measurements have little clini-cal utility for diagnosis of thyroid carcinoma. TPA was identified in various kinds of carcinomas and carcinoma cell lines by Björklund (17) using antibodies raised against insoluble residuces extracted from pooled human tumor, and has been recognized as a good tumor marker (3,(6)(7)(8)(9)(10)(11). TPA was identified in various kinds of carcinomas and carcinoma cell lines by Björklund (17) using antibodies raised against insoluble residuces extracted from pooled human tumor, and has been recognized as a good tumor marker (3,(6)(7)(8)(9)(10)(11).…”

“…Recently, Björklund et al (5) described that among 35 epitopes of TPA, the M3 epitope characterized proliferating tumor cells. Tissue polypeptide specific antigen (TPA) is a marker utilizing a specific epitope of TPA and is able to assist in predicting prognosis and response to treatment in a variety of cancers, including lung (6), breast (7), prostatic (8), pancreatic (9), ovarian (10), and cervical cancers (11). The TPS level in serum does not simply reflect the mass of the tumor, as is assumed for other tumor markers, but reflects the tumor cell activity (5).…”

Tissue polypeptide-specific antigen in pediatric patients: Assessment of normal values

“…The value of this tumor marker was investigated in clinical trials on breast [10,11], ovary [12], prostate, renal [9,13], and colon [14] cancer.…”

Tissue polypeptide specific antigen in the post therapeutic evaluation of patients with ovarian and colorectal cancer

“…High levels of TPS and CA125 were also reported in ovarian cancer compared to benign gynecological diseases. TPS and CA125 were higher in advanced stages of cancer compared to early stages (2,16). It was observed that serum TPS and CA125 reflect the course of the neoplastic process during chemotherapy (17).…”

“…It was observed that serum TPS and CA125 reflect the course of the neoplastic process during chemotherapy (17). Also, TPS and CA125 levels could be used as good predictors of recurrence in ovarian cancer (16). TPS in combination with CA125 has improved the detection of recurrent ovarian cancer (8) and in combination they increase the prognostic accuracy after chemotherapy (18).…”